Forbes on Nostr: A Predictive Healthcare Visionary Is Optimistic About Solving America’s Opioid ...
A Predictive Healthcare Visionary Is Optimistic About Solving America’s Opioid Addiction And Chronic Pain Epidemic
==========
American workers are increasingly experiencing chronic pain and opioid addiction. More than 1 in 5 Americans experienced chronic pain in 2021. Chronic pain is more prevalent and costly than cancer, diabetes, and heart disease combined. Chronic pain is linked to an average loss of 5.4 work hours per week, costing the US economy up to $300 billion annually. Health technology entrepreneur Brian Meshkin's companies, Proove Genomics and Outcomeus, use a predict-and-prevent approach, leveraging advanced genetics and information technology. Proove Genomics offers personalized medicine lab testing that can assess pain sensitivity for 96% of the population and determine patient risk of opioid use disorder with up to 96.7% accuracy. Meshkin highlights the medical and pharmaceutical industries' reluctance to move away from the current trial and error standard. He attributes this market resistance to the government. Meshkin aims to shift the American healthcare system into a predictive model by valuing medical individuality, reducing poor decision-making costs, expanding access to quality care, increasing lifespan and quality of life, and prioritizing proven treatments. Meshkin refers to Proove Genomics, Outcomeus, and other ventures as the "positive impact armada" and aims to reduce pain incidence and duration worldwide. Meshkin's predict-and-prevent strategy aims to resolve healthcare problems, including access, quality, and financial resources.
#OpioidAddiction #ChronicPain #Healthcare #PredictiveHealthcare #Genetics #InformationTechnology
https://www.forbes.com/sites/zengernews/2024/04/26/a-predictive-healthcare-visionary-is-optimistic-about-solving-americas-opioid-addiction-and-chronic-pain-epidemic/
==========
American workers are increasingly experiencing chronic pain and opioid addiction. More than 1 in 5 Americans experienced chronic pain in 2021. Chronic pain is more prevalent and costly than cancer, diabetes, and heart disease combined. Chronic pain is linked to an average loss of 5.4 work hours per week, costing the US economy up to $300 billion annually. Health technology entrepreneur Brian Meshkin's companies, Proove Genomics and Outcomeus, use a predict-and-prevent approach, leveraging advanced genetics and information technology. Proove Genomics offers personalized medicine lab testing that can assess pain sensitivity for 96% of the population and determine patient risk of opioid use disorder with up to 96.7% accuracy. Meshkin highlights the medical and pharmaceutical industries' reluctance to move away from the current trial and error standard. He attributes this market resistance to the government. Meshkin aims to shift the American healthcare system into a predictive model by valuing medical individuality, reducing poor decision-making costs, expanding access to quality care, increasing lifespan and quality of life, and prioritizing proven treatments. Meshkin refers to Proove Genomics, Outcomeus, and other ventures as the "positive impact armada" and aims to reduce pain incidence and duration worldwide. Meshkin's predict-and-prevent strategy aims to resolve healthcare problems, including access, quality, and financial resources.
#OpioidAddiction #ChronicPain #Healthcare #PredictiveHealthcare #Genetics #InformationTechnology
https://www.forbes.com/sites/zengernews/2024/04/26/a-predictive-healthcare-visionary-is-optimistic-about-solving-americas-opioid-addiction-and-chronic-pain-epidemic/